GuidelineZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2022
[Guideline for the prevention and treatment of hepatitis C (2022 version)].
Guideline in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- [Meta-analysis of the efficacy of the Fuzheng Huayu formula in the treatment of hepatitis B-associated liver fibrosis or cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Pooled it
- [Guidelines on the management of ascites in cirrhosis (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Guideline
- [A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Trial
- [Recent advances in epidemiology, prevention and treatment of hepatitis C in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Community-based interventions for hepatitis C virus elimination among people who use drugs in Shanghai, China.Harm reduction journal · 2026Article
- Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination.Journal of viral hepatitis · 2026Article
- Chinese Guidelines for Clinical Diagnosis, Treatment, and Management of Cirrhosis (2025).Journal of clinical and translational hepatology · 2026Article
- Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024).Journal of clinical and translational hepatology · 2025Article
- [Clinical practice and challenges from simple models to precise integration for serological evaluation of a non-invasive diagnosis of liver fibrosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- The role of tenofovir-based HIV pre-exposure prophylaxis in preventing HBV infection among men who have sex with men: insights from China.Infectious diseases of poverty · 2025Article
- Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.Clinical and molecular hepatology · 2025Article
- Epidemiological characteristics and treatment challenges of chronic hepatitis C in the kashi region of xinjiang china: A retrospective investigation from 2018 to 2022.Scientific reports · 2025Article
- [Analysis of the results of the Fuxing Program Action for micro-elimination of hepatitis C in Zhuhai].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Gut microbiota in liver diseases: initiation, development and therapy.Frontiers in medicine · 2025Review
- Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents.Infection and drug resistance · 2025Article
- Self-management and its association with coping styles and disease-related stigma in patients with chronic hepatitis C.Frontiers in public health · 2025Article
- Long-term spatial-temporal evolution of hepatitis C burden in eastern China: a retrospective case analysis from Wuxi City.Frontiers in public health · 2025Article
- Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.Infectious diseases and therapy · 2025Article
- [Study on hepatitis C intervention measures to improve the referral, treatment, and cure rate in hospitals].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to update the prevention, diagnosis and antiviral therapy for hepatitis C and to achieve the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030; Chinese Medical Association, the Chinese Society of Hepatology, and the Society of Infectious Diseases organized relevant experts in 2019 to update the guidelines for the prevention and treatment of hepatitis C (2019 version) based on the basic and clinical research progress of hepatitis C infection, combined with the present situation of our country, so as to provide an important basis for the prevention, diagnosis and treatment of hepatitis C. Since the end of 2019, the screening and management strategy of hepatitis C has been further updated. More and more direct antiviral agents, especially pan genotypic agents including those developed and produced by domestic enterprises, have been included in the national basic medical insurance directory. The accessibility of drugs has significantly increased. In 2022, experts updated the recommendations on prevention and treatment again.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.